Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Skye Bioscience, Inc. Director's Dealing 2018

Mar 3, 2018

34097_dirs_2018-03-02_1e258ba3-1b8d-40c5-9a69-ca9c7018a753.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Nemus Bioscience, Inc. (NMUS)
CIK: 0001516551
Period of Report: 2018-01-24

Reporting Person: Emerald Health Sciences Inc. (10% Owner)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2018-01-24 Common Stock X 1781250 $0.001 Acquired 40781250 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2018-01-24 Common Stock Warrant (Right to Buy) $0.001 X 1781250 Disposed 2020-08-20 Common Stock (1781250) Direct